Sinotherapeutics (SH:688247) Xin Lang Cai Jing·2025-11-04 08:52Core Viewpoint - Nanjing Qihe Venture Capital Partnership (Limited Partnership) has completed its share reduction plan for Xuantai Pharmaceutical, selling a total of 3.218 million shares, which represents a reduction of 0.7098% of its holdings [1] Summary by Sections - Shareholding Details - The shareholder originally held 25.798 million shares, accounting for 5.6907% of the total shares [1] - After the reduction, the current holding is 22.58 million shares, representing 4.9808% of the total shares [1] - Reduction Plan - The reduction plan was implemented from August 5, 2025, to November 4, 2025 [1] - The shares were sold through centralized bidding at a price range of 10.5 to 13.13 yuan per share [1] - The total cash generated from the sale was approximately 37.4141 million yuan [1]